Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06700096 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Study acronym: MAGNOLIA
StatusRecruiting
PhasePhase 3
SponsorBiocad
Started2024-11-07
View on ClinicalTrials.gov ↗

Amendment history

2025-11-17
Study Status, Contacts/Locations v3
Study sites11→14
2025-06-10
Study Status, Arms and Interventions v2
Re-verified, no change to tracked fields
2025-02-19
Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-12→confirmed 2024-11-07
Study sitesdetails revised at 11 of 11 sites
Study titlerevised
An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients withWith Hemophilia B
2024-11-19
Original filing
Biocad
26 trials monitored
See all monitored trials
Hemophilia
231 trials monitored
See 10 trials at risk
The aim of the study is to demonstrate non-inferiority of ANB-002 compared with preventive use of coagulation factor IX (FIX) in adult subjects with hemophilia B with FIX activity ≤2% and without FIX inhibitor. The study will have an open-label single-arm design.
Trial Details
NCT Number NCT06700096
Lead Sponsor Biocad
Conditions Hemophilia B
Enrollment 24 participants
Start Date 2024-11-07
Primary Completion 2027-04 (estimated)
Study Completion 2032-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-18